Colony-stimulating factor 1 receptor blockade prevents fractionated whole-brain irradiation-induced memory deficits by X. Feng et al.
RESEARCH Open Access
Colony-stimulating factor 1 receptor
blockade prevents fractionated whole-brain
irradiation-induced memory deficits
Xi Feng1,2, Timothy D. Jopson1,2, Maria Serena Paladini1,2, Sharon Liu3, Brian L. West4, Nalin Gupta3,5
and Susanna Rosi1,2,3*
Abstract
Background: Primary central nervous system (CNS) neoplasms and brain metastases are routinely treated with
whole-brain radiation. Long-term survival occurs in many patients, but their quality of life is severely affected by the
development of cognitive deficits, and there is no treatment to prevent these adverse effects. Neuroinflammation,
associated with activation of brain-resident microglia and infiltrating monocytes, plays a pivotal role in loss of
neurological function and has been shown to be associated with acute and long-term effects of brain irradiation.
Colony-stimulating factor 1 receptor (CSF-1R) signaling is essential for the survival and differentiation of microglia
and monocytes. Here, we tested the effects of CSF-1R blockade by PLX5622 on cognitive function in mice treated
with three fractions of 3.3 Gy whole-brain irradiation.
Methods: Young adult C57BL/6J mice were given three fractions of 3.3 Gy whole-brain irradiation while they were
on diet supplemented with PLX5622, and the effects on periphery monocyte accumulation, microglia numbers, and
neuronal functions were assessed.
Results: The mice developed hippocampal-dependent cognitive deficits at 1 and 3 months after they received
fractionated whole-brain irradiation. The impaired cognitive function correlated with increased number of periphery
monocyte accumulation in the CNS and decreased dendritic spine density in hippocampal granule neurons.
PLX5622 treatment caused temporary reduction of microglia numbers, inhibited monocyte accumulation in the
brain, and prevented radiation-induced cognitive deficits.
Conclusions: Blockade of CSF-1R by PLX5622 prevents fractionated whole-brain irradiation-induced memory deficits.
Therapeutic targeting of CSF-1R may provide a new avenue for protection from radiation-induced memory deficits.
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Background
Whole-brain irradiation (WBI) is commonly used for the
treatment of primary brain tumors and brain metastases.
Most patients with primary brain tumors are treated to a
total dose of 55–60 Gy delivered in 25–30 fractions. A
variety of conformal strategies are used to reduce dose
to remote areas of the brain. This contrasts with a total
dose of 18–20 Gy used for CNS treatment of children
with leukemia. Overall survival is improved with modern
treatment techniques [1, 2], but patients still experience
adverse late effects. Following fractionated whole-brain
irradiation (fWBI), 50–90 % of long-term survivors
(>6 months) have irreversible cognitive decline [3, 4].
The underlying molecular mechanisms that result in the
loss of cognitive function after radiotherapy are not com-
pletely understood, and consequently, there is no treatment
to prevent these adverse effects. Improving the quality of
life of the growing population of patients who have received
radiation treatment is an important objective.
WBI causes a number of deleterious cellular responses
including neuronal dysfunction, blood–brain-barrier dam-
age, astrocyte and microglia activation, and infiltration of
peripherally derived monocytes [5–12]. WBI induces
apoptosis of neural progenitor cells [8], which would be
expected to affect overall cognitive function. Transplant-
ation of neural stem cells in rodents can ameliorate
radiation-induced cognitive dysfunction [13]. Neuronal in-
jury and loss is not the only pathway contributing to cog-
nitive deficits, since activation of non-neuronal cell types
also affects overall brain function. We and others have
shown that radiation induces infiltration of peripheral
myeloid cells that depend on CCR2 signaling [14, 15] and
that loss of the cytokine receptor CCR2 prevented the de-
velopment of radiation-induced long-term cognitive defi-
cits with no influence on neurogenesis [15]. Recently, Piao
et al. demonstrated that oligodendrocyte progenitors de-
rived from human embryonic stem cells can remyelinate
the brain and rescue radiation-induced behavior deficits
[16]. However, there is no clinically available agent that
targets these convergent pathways in order to ameliorate
or prevent permanent loss of cognitive function induced
by WBI.
WBI induces up-regulation of pro-inflammatory cyto-
kines and chemokines, including CCL2 [5, 17], which
facilitates the recruitment of CCR2+ monocytes into
the CNS. Following a single dose of 10 Gy WBI, dele-
tion of CCL2 ameliorates deficits in hippocampal
neurogenesis [18]. We demonstrated an increase of
monocyte accumulation in the brain, as well as a de-
crease of microglia, 7 days following a single dose of
10 Gy WBI [5]. The recruitment of circulating mono-
cytes into the CNS is regulated by the production of a
number of soluble chemokines that interact with their
cell surface receptors. One of these, colony-stimulating
factor 1 receptor (CSF-1R), is a transmembrane tyrosine
kinase receptor encoded by the c-fms proto-oncogene
[19]. CSF-1/CSF-1R signaling regulates the survival, prolif-
eration, chemotaxis, and differentiation of monocytes and
macrophages [20–22]. Loss of CSF-1R results in complete
elimination of microglia and severe monocyte deficits
[23–25], and mice lacking CSF-1 have markedly reduced
numbers of microglia [26].
Our group, and others, has used a single dose of WBI
to model radiation-induced brain injury. However, in clin-
ical treatment, virtually all patients receive fractionated
brain irradiation with the goal of reducing toxicity to nor-
mal tissue. Here, we model the effects of fWBI in young
adult mice by using a fractionated treatment paradigm
(3 × 3.3 Gy) and explore the outcomes of CSF-1R blockade
by PLX5622, analog of another CSF-1R inhibitor PLX3397
[27]. In other preclinical studies, PLX5622 has been used
to diminish peripheral monocytes/macrophages [28, 29].
Similar to PLX3397, treatment with higher dose of
PLX5622 (1200 ppm) depletes microglia in the CNS
[28–34]. Recently, Dagher et al. showed that PLX5622
treatment (300 ppm) ameliorated cognitive deficits in
aged Alzheimer’s mice [32]. In addition, our preliminary
results (data not shown) suggest that lower (300 ppm) and
higher (1200 ppm) doses of PLX5622 treatment achieved
similar effect in reducing circulating monocytes in the
periphery. In light of these results, we treated young adult
mice with lower dose of PLX5622 (300 ppm) and evalu-
ated cognitive outcomes at 1 month after fWBI, the earli-
est time point we see cognitive deficits in our hands. Our
data show that fractionated brain irradiation, similar to
single-dose irradiation, results in hippocampal-dependent
memory deficits and loss of dendritic spine density in hip-
pocampal granule neurons. Strikingly, CSF-1R blockade
by PLX5622 can prevent memory deficits and dendritic
spine density loss in mice treated with fWBI. Flow cytom-
etry analyses of myeloid populations following treatment
with PLX5622 demonstrate a strong correlation between
improved cognitive performance and both decreased
microglia numbers and monocyte accumulation in the
brain. Using a clinically relevant model and pharmaco-
logic approach, our data show that CSF-1R blockade by
PLX5622 can prevent fWBI-induced cognitive deficits
in mice by preventing loss of synaptic dendritic spines.
These data implicate a new and therapeutically tract-
able role for infiltrating monocytes and microglia after
brain irradiation in loss of synaptic function.
Methods
Compound
Control and PLX5622 (300 ppm formulated in AIN-76A
standard chow, Research Diets, Inc.) chows were provided
by Plexxikon Inc (Berkeley, CA). Approximately 1.2 mg of
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PLX5622 was ingested by each mouse per day (calculation
based on 4 g/mouse chow daily).
Animal procedures
All animal experiments were conducted in compliance
with animal protocols approved by the Institutional
Animal Care and Use Committee at the University of
California, San Francisco (UCSF), following the National
Institutes of Health Guidelines for animal care. C57BL/6J
male mice were purchased from the Jackson Laboratory.
CX3CR1+/GFP/CCR2+/RFP animals were generated by
crossing CX3CR1GFP/GFP/CCR2RFP/RFP with C57BL/6J
mice as previously described [5]. Starting at 8 weeks
old, C57BL/6J mice were treated with PLX5622 or con-
trol chow for 21 days. Cranial irradiation started 7 days
after drug treatment was initiated. Mice used for Golgi
staining were euthanized at the end of the first NOR
test (33 days after fWBI) were euthanized and perfused
with ice-cold PBS, and the right hemispheres were used
for Golgi staining. Mice used for flow cytometry ana-
lyses were euthanized at indicated time relative to the
last day of fWBI.
Radiation treatment
All the mice were anesthetized with intraperitoneal in-
jection of a ketamine (100 mg/kg)/xylazine (10 mg/kg)
mix and placed 16.3 cm from a cesium-137 source (JL
Shepherd & Associates). The eyes and body were
shielded by a lead collimator that limited the beam to a
width of 1 cm. An extra lead plate was used to block ex-
posure of the trachea. Irradiated groups received 1.65 Gy
of irradiation on both side of the head to accumulate
3.3 Gy for each fractionated irradiation. Three fractions
were delivered every other day over 5 days to accumu-
late a total dose of 10 Gy. Sham animals underwent the
same procedures without radiation.
Novel object recognition test
All the mice used for the NOR test were housed in a
room with reversed light cycle (12 light/12 dark) for at
least 2 weeks before tests. Tests were conducted during
the dark cycle. The mice were handled 5 min each day
for 5 days before habituation. An open arena (30 cm ×
30 cm × 30 cm; L ×W×H) was placed in a dimly lit be-
havior test room with an overhead camera. The mice
were allowed to explore the open arena for 10 min for
two consecutive days. On day 3, two identical objects
were placed in the arena and mice were allowed to explore
for 5 min. On day 4, one of the objects was replaced by a
novel object and mice were allowed to explore for 5 min
(Additional file 1: Figure S1A). Trials were recorded by
the overhead camera and analyzed by an automatic video
tracking system (EthoVision, Noldus) for movement
tracking or by manual scoring for exploratory behavior.
Exploratory behavior was defined as the animal directing
its nose toward an object at a distance less than 2 cm.
Objects were secured in the arena with magnets. Arena
and objects were wiped with 70 % ethanol between trials
to eliminate odor cues.
Delayed matching-to-place dry maze test
Delayed matching-to-place (DMP) dry maze test was
used to measure special working memory as described
by Faizi et al. [35]. Briefly, we used a modified Barnes
maze with 40 escape holes (D = 5 cm, 16 holes on the
outer ring with 50-cm distance to the center, 16 holes
on the middle ring with 35-cm distance to the center,
and 8 holes on the inner ring with 20-cm distance to the
center). All holes were uncovered with the exception of
the escape hole, which is covered with a dark escape
tube (a black PVC tube). The light was set to approxi-
mately 1200 lux, and a noise (2 kHz, 85 dB) was used
during the test. Visual cues were placed on three sides of
the maze. Mice were giving four trials each day with
interval of 10 min. Mice were placed at the center of the
maze under a dark box for 30 s. The trial started when
the box was removed and ended when the mice found
the escape hole within 90 s. Mice were guided to the es-
cape hole by the experimenter if they could not find it
within 90 s. Noise was turned off, and the escape hole
was covered immediately after the mice entered. The
mice were returned to their home cage after a 10-s delay.
The maze surface and the escape tube were cleaned with
70 % ethanol (v/v) after each trial to minimize odor cues.
The escape tube was kept at the same location and
changed on each test days. Trials were recorded by an
overhead camera and analyzed by Ethovision (Ethovision,
Noldus).
Metric distance test
Metric distance test was used to measure hippocampal
function as previously described by Goodrich-Hunsaker
et al. [36] with alterations to suit test in mice (Additional
file 1: Figure S1E). Briefly, the test was performed on
two consecutive days during the dark cycle with one ha-
bituation phase and 3 trials each day. On day 1, the mice
were put into an open arena (30 cm × 30 cm × 30 cm,
L ×W×H) for 5 min. On trial 1, the mice were put into
the arena with two identical objects placed at a distance
of 28 cm to each other for 5 min. On trial 2, the mice
were put into the arena with the same setting as trial 1
for 5 min. On trial 3, the distance between the objects
was shortened to 14 cm and the mice were allowed to
explore for 5 min. There was a 3-min interval between
each trial, and the mice were put back into their home
cage after each trial. One day 2, all trials were performed
with the same setting as day 1 except that the distance
between objects on trial 3 was changed to 21 cm. The
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objects and the arena were cleaned with 70 % (v/V)
ethanol after each trial to minimize odor cues. Trials
were recorded, and total time exploring the object pair
was scored. Total time exploring during trial 1 on each
test day was used as baseline of exploration.
Flow cytometry
The mice used for flow cytometry analysis were eutha-
nized and perfused with ice-cold PBS. The brains were
removed and immediately placed into ice-cold HBSS.
Brain samples were then dissociated using a Neural Tis-
sue Dissociation Kit (P) (Miltenyi Biotec). Dissociated
cells were resuspended in 10 ml of 30 % Percoll solution
(Sigma) in an RPMI medium and laid over a 1 ml 70 %
Percoll solution layer. After centrifugation at 800g for
30 min at 4 °C, interphase cells were transferred to a
new 15-ml Falcon tube and washed with RPMI. Cell pel-
lets were resuspended with FACS buffer (DPBS with
0.5 % BSA fraction V) and blocked with one volume of
blocking solution (5 % normal mouse serum, 5 % normal
rat serum, 5 % normal rabbit serum, 2 % FBS, and 1 %
BSA fraction V in ×1 DPBS) for 30 min and stained for
30 min with fluorophore-conjugated antibodies on ice
(CD45-BV711, CD11b-AF700, Ly6C-Pacific Blue, and
Ly6G-PE were purchased from BD Pharmingen); 7AAD
was used to exclude dead cells. Data were collected on
an Aria III sorter (BD) and analyzed with FlowJo v10
software (Tree Star Inc.). At least 20,000 and 200,000 vi-
able events were collected from each brain and blood
sample, respectively.
Golgi staining
Brain hemispheres stayed in Golgi staining solution (A
Modified Golgi-Cox Stain for Neural Cells, Docket No.
D4433, Cornell University) for 14 days and were trans-
ferred into 30 % sucrose in ×1 PBS overnight at 4 °C.
The next day, tissues were transferred into fresh 30 %
sucrose solution, protected from light and stored at 4 °C
for at least 2 days. Brains were cut into 100 μm sections
with a vibratome (VT1000 S, Leica, Wetzlar, Germany),
mounted on gelatin pre-treated slides and dried for
2 days. Samples were then developed with the develop-
ing solution (A Modified Golgi-Cox Stain for Neural
Cells, Docket No. D4433, Cornell University), covered,
and dried. Images were taken on a Keyence 7000 system
under a ×100 objective lens with immersion oil for hip-
pocampal granule neurons. For each sample, 18–30 im-
ages were taken (2–3 images per section, 8–12 sections
per mouse, N = 5–6 per treatment group) and used for
dendritic spine density analysis. All protrusions from the
dendrites were manually counted as spines regardless of
morphology. A total length of at least 3000 μm of den-
drites was analyzed from each animal using ImageJ
(National Institutes of Health).
Statistical analysis
NOR test results are shown as mean percentage of time
spent on exploring each object (time exploring familiar
or novel object/total exploring time) or mean discrimin-
ation index ((time exploring novel object − time explor-
ing familiar object)/total exploring time) ± SEM. Metric
distance test results are shown as percentage of time
spent on exploring both objects in trial 1 on each test
day. Results for DMP and metric distance tests were an-
alyzed with ordinary two-way ANOVA with Bonferroni’s
test for post hoc comparisons using day and experimen-
tal group as independent factors. Results for NOR test,
dendritic spine density analysis, and flow cytometry with
PLX5622 and fWBI treatments were analyzed with or-
dinary two-way ANOVA with Tukey’s test for post hoc
comparisons using PLX5622 and fWBI as independent
factors. Results for temporal analysis of monocyte accu-
mulation were analyzed with one-way ANOVA with
Bonferroni’s test for post hoc comparisons. All other
comparisons between two sets of data were determined
using t test. Error bars are shown as mean ± SEM. De-
tails of each statistical analysis were described in figure
legends. Graphs were analyzed and plotted with Graph-
Pad Prism 6 software (GraphPad Software, Inc).
Results
Fractionated brain irradiation causes persistent
hippocampal-dependent memory deficits
The hippocampus, located in the medial temporal lobes
of the brain, is responsible for memory formation. It has
been suggested that the severity of cognitive impairment
in humans depends upon the dose of radiation delivered
to the hippocampus [37]. To determine the effects of
therapeutically relevant fractionated doses of irradiation
on hippocampal-dependent memory, adult male C57BL/
6J mice were treated with three fractions of 3.3 Gy ir-
radiation every other day to a total dose of 10 Gy and
tested with a series of cognition tests at different time
points (Fig. 1a). All mice tolerated fWBI and gained
weight normally through the duration of study (data not
shown). Hippocampal-dependent recognition memory
was measured by the NOR test 4 and 13 weeks after the
last fraction of radiation (Additional file 1: Figure S1A).
In the 4 weeks’ NOR test, the mice in the non-irradiated
group showed significantly higher preference toward the
novel object (familiar = 36.32 ± 9.75 %; novel = 63.68 ±
9.75 %; p < 0.0001) while mice in the irradiated group
had no preference toward either object (familiar =
46.82 ± 7.32 %; novel = 53.18 ± 7.32 %; p > 0.05. Fig. 1b).
Consistent with these observations, the discrimination
index was reduced in the irradiated group (p < 0.01)
(Fig. 1c). There was no difference in distance traveled
or total exploring time between the sham and irradiated
groups (Additional file 1: Figure S1B and C). We observed
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similar results in the 13 weeks’ NOR test (Fig. 1d, 0 Gy
familiar = 32.03 ± 2.89 %; 0 Gy novel = 67.97 ± 2.89 %, p <
0.0001; 3 × 3.3 Gy familiar = 47.22 ± 6.88 %; 3 × 3.3 Gy
novel = 52.78 ± 6.88 %; and Fig. 1e, p < 0.001). The matrix
distance test (Additional file 1: Figure S1E) was also
used to evaluate hippocampal-dependent memory deficits
Fig. 1 Fractionated whole-brain irradiation causes persistent hippocampal-dependent memory deficits. a Schematic charts of experiment timeline
and cognition tests paradigm. Fractionated irradiation was delivered at 3.3 Gy/day every other day; NOR test was performed 4 and 13 weeks after
the last radiation fraction; DMP tests were performed at 5 and 12 weeks after fWBI; matrix distance test was performed 8 weeks after fWBI. b Analysis
of NOR at 4 weeks after fWBI (day 4 of NOR test, ****p < 0.0001, ns = not significant, n = 17, t test). c Discrimination index analysis for the NOR task
(**p < 0.01, n = 17, t test). d Results of NOR at 13 weeks after fWBI (****p < 0.0001, ns = not significant, n = 7–8, t test). e Discrimination index
analysis for the NOR test at 13 weeks post fWBI (***p < 0.001, n = 7–8, t test). f DMP test showed no impairment in working memory after fWBI
(n = 7–8, two-way ANOVA). g Matrix distance test day 1, animals in the sham group but not in the irradiated group had significantly increased
exploring time in trial 3 compared to trial 1 (**p < 0.01, n = 7–8, two-way ANOVA). (h) Matrix distance test day 2, only the animals in the sham
group had significantly increased exploring compared to trial 1 (*p < 0.05, n = 7–8, two-way ANOVA)
Feng et al. Journal of Neuroinflammation  (2016) 13:215 Page 5 of 13
8 weeks after fWBI (Fig. 1a). Sham animals could detect
both large and small changes in object locations and spent
more time exploring the object pair in novel locations
while irradiated animals failed to recognize these changes
(Fig. 1g, p < 0.01, and Fig. 1h, p < 0.05). There was no sig-
nificant difference in total exploring time during both test
days (Additional file 1: Figure S1F and G). Working
memory was measured by DMP test at 5 and 12 weeks
after irradiation (Fig. 1a). We observed no significant
difference in latency to the first escape hole between
sham and irradiated animals at both time points (Fig. 1f
and data not shown). There was no significant differ-
ence in velocity between sham and irradiated groups
during the tests (Additional file 1: Figure S1D). Taken
together, these results suggest that fractionated whole-
brain radiation impairs hippocampal-dependent memory
without affecting working memory in mice.
CSF-1R blockade prevents hippocampal-dependent
memory deficits after fractionated irradiation
To investigate the effects of CSF-1R blockade on cogni-
tion after fWBI, we treated mice with PLX5622 (300 ppm)
in chow for a total of 21 days, starting from 7 days before
irradiation. The NOR test was performed 4 weeks after
the last fraction of WBI (Fig. 2a). The bioanalysis of
PLX5622 revealed that drug concentrations remained
comparable throughout the treatment (Additional file 2:
Figure S2A). As expected, animals on a control diet
showed impaired memory after fractionated WBI (control
sham: familiar = 41.38 ± 2.76 %; novel = 58.62 ± 2.76 %,
p < 0.001; control IRR: familiar = 49.43 ± 2.12 %; novel =
50.57 ± 2.12 % p > 0.05) while PLX5622-treated mice
showed no deficits (PLX5622 sham: familiar = 32.46 ±
1.70 %; novel = 67.54 ± 1.70 %, p < 0.0001; PLX5622 IRR:
familiar = 36.32 ± 2.25 %; novel = 63.68 ± 2.25 %, p <
0.0001; Fig. 2b). The discrimination index analyses re-
vealed a significant difference between the sham and irra-
diated groups on a control diet (control sham= 21.08 ±
4.33 %; control IRR = 1.145 ± 4.24 %; p < 0.05). Following
PLX5622 treatment, there was no significant difference in
the discrimination index between the sham and irradiated
groups (PLX sham = 30.34 ± 5.67 %; PLX IRR = 27.37 ±
4.50 %; p > 0.05; Fig. 2c). There was no significant differ-
ence in total traveled distance or total exploring time
among all experiment groups on the test day (Additional
file 2: Figure S2B and C). These results demonstrate that
treatment with PLX5622 for a brief period that precedes
and follows irradiation can fully prevent fWBI-induced
hippocampal-dependent memory deficits.
CSF-1R blockade protects against dendritic spine loss
after fractionated irradiation
Hippocampal neurogenesis is important for special and
object recognition memory [38, 39]. Given the significant
decrement in hippocampal-dependent memory induced
by fWBI, we next sought to determine if the cognitive def-
icits were related to changes at the synaptic level in the
hippocampus. We used Golgi staining to quantify den-
dritic spine density of granule cells in the dentate gyrus
(DG) (Fig. 2d). We did not observe significant changes in
dendritic spine densities at the end of PLX5622 treatment
(day 10 post fWBI, Additional file 2: Figure S2D). How-
ever, at 33 days post fWBI, there is a significant reduction
of dendritic spine density in irradiated animals (control
sham= 3.359 ± 0.119/10 μm; control IRR = 2.676 ± 0.098/
10 μm; p < 0.01). Strikingly, CSF-1R blockade with
PLX5622 prevented dendritic spine density loss and re-
sulted in increased dendritic spine density after fWBI
(PLX5622 sham = 3.191 ± 0.115/10 μm; PLX5622 IRR =
3.638 ± 0.077/10 μm; p < 0.05). There was no significant
difference between the control sham and PLX5622
sham groups (Fig. 2e, Additional file 3: Table S1).
Fractionated WBI induces acute delayed monocyte
accumulation in the brain
To determine the temporal dynamics of monocyte accu-
mulation after fWBI, we used CX3CR1+/GFPCCR2+/RFP
reporter mice and flow cytometry analyses of the micro-
glial and mononuclear cell populations. We first measured
the numbers of Cd11b+GFP+RFP+ cells, which represent
blood-derived monocytes [40] (Fig. 3a). There was no sig-
nificant change in this population after each radiation
fraction (sham = 0.095 ± 0.037 %, day −3 = 0.060 ±
0.013 %, day −1 = 0.098 ± 0.031 %, and day 1 = 0.070 ±
0.006) until 3 days after the last fraction (day 3 = 0.166 ±
0.029 %, p < 0.01), which recovered after day 7 (day 7 =
0.085 ± 0.022 %, p > 0.05, day 14 = 0.060 ± 0.004 %, day
33 = 0.090 ± 0.017 %. Additional file 4: Figure S3A). We
observed a significant increase in the inflammatory
monocyte population (CD45+GFP+RFP+Ly6Chigh cells)
at day 3 and day 7 after the last radiation fraction
(sham= 0.039 ± 0.016 %, day −3 = 0.028 ± 0.012 %, day −1 =
0.046 ± 0.006 %, day 1 = 0.025 ± 0.006 %, day 3 = 0.094 ±
0.026 %, day 7 = 0.072 ± 0.011 %, day 14 = 0.017 ± 0.007 %,
day 34 = 0.027 ± 0.007 %, Fig. 3b). There was no signifi-
cant change in the CD45+GFP+RFP+Ly6Clow population
(Additional file 4: Figure S3B). The population expressing
only RFP (GFP−RFP+) remained unchanged throughout
the experiment (Additional file 4: Figure S3C). The micro-
glial population, represented by cells expressing only
GFP (GFP+RFP−), remained unchanged until 7 days
after the last radiation fraction, then declined by 35 %,
followed by recovery after day 14 (sham = 13.68 ±
2.27 %, day −3 = 12.00 ± 2.45 %, day −1 = 16.58 ± 2.33 %,
day 1 = 15.18 ± 3.029 %, day 3 = 10.97 ± 0.98 %, day 7 =
7.95 ± 1.15 %, day 14 = 10.97 ± 0.34 %, day 30 = 11.34 ±
1.11 %, Fig. 3c). Taken together, these results demon-
strate that fractionated cranial irradiation induces
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Fig. 2 (See legend on next page.)
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Ly6Chigh monocyte accumulation in an acute delayed
pattern.
CSF-1R blockade results in reduced blood monocytes and
prevents monocyte accumulation in the brain after fWBI
CSF-1R is expressed in blood monocytes and is important
for the survival, maturation, and differentiation of these
cells [26, 41]. We analyzed blood samples from WT mice
subjected to fWBI, and we observed a 35 % reduction of
CD11b+Ly6G−Ly6Chigh monocytes after 7 and 14 days of
PLX5622 treatment (day −4: control = 10.23 ± 1.090 %,
PLX5622 = 6.233 ± 0.671 %, p = 0.0102; day 3: control
sham = 20.47 ± 1.562 %, PLX sham = 13.57 ± 0.967 %,
p = 0.0106, control IRR = 20.50 ± 1.864 %, PLX5622
IRR = 13.27 ± 0.595 %, p = 0.0118; Fig. 4a–c). Importantly,
there were no significant changes in Ly6Clow monocytes
or neutrophils (Additional file 5: Figure S4A and B). These
results suggest that the Ly6Chigh-expressing monocytes
are susceptible to CSF-1R blockade while the Ly6Clow-
expressing monocytes are not affected. Further analysis
of the brain samples revealed that PLX5622 treatment
alone did not cause change in the numbers of Ly6Chigh
monocytes (Fig. 4d, e). Similar to results seen in
CX3CR1+/GFPCCR2+/RFP reporter mice, fractionated
brain irradiation significantly increased Ly6Chigh mono-
cytes (ctrl sham = 100.0 ± 9.8 %, ctrl IRR = 206.4 ± 30.5 %,
p = 0.0017, Fig. 4f). However, when treated with PLX5622
no significant difference was detected (PLX5622 sham=
100.0 ± 11.47 %, PLX5622 IRR = 92.65 ± 15.12 %, p > 0.05;
Fig. 4f ). There was no change in the numbers of
CD45+CD11b+Ly6ClowLy6Gneg monocytes or CD45
+CD11b+Ly6C+Ly6G+ neutrophils (Additional file 5:
Figure S4 A and B). These results suggest that the in-
hibition of monocyte accumulation in the CNS by
CSF-1R blockade is possibly due to reduced numbers
of circulating monocytes in the blood.
Fig. 3 Fractionated irradiation induces inflammatory monocyte accumulation in the brain. a Representative images of gating strategy used in flow
cytometry analyses. b Analysis showing temporal dynamics of inflammatory monocyte accumulation after fWBI (**p < 0.01, ****p < 0.0001, n = 4–5,
one-way ANOVA). c Temporal dynamics of the GFP-only population in the brain after fWBI (**p < 0.01, n = 4–5, one-way ANOVA)
(See figure on previous page.)
Fig. 2 CSF-1R blockade prevents memory deficits and loss of dendritic spines after fractionated irradiation. a Schematic chart of experiment
design. Mice were treated with PLX5622 7 days before the first radiation fraction and continued for a total of 21 days. NOR test was performed
4 weeks after the last radiation fraction. Mice were euthanized 1–2 days after the NOR test for Golgi staining. b Analysis of percentage time spent
in exploring each object on test day (***p < 0.001, ****p < 0.0001, n = 11–12, t test). c Discrimination index analysis for the NOR task (*p < 0.05, ns = not
significant, compared to control sham; FPLX5622 = 13.99, p = 0.0005; FIRR = 5.825, p = 0.0201; FInteraction = 3.198, p = 0.0808; n = 11–12, two-way ANOVA).
d Representative images of dendrites from Dentate Gyrus granule neurons (×100, scale bar = 10 μm). e Comparison of dendritic spine densities
(*p < 0.05, **p < 0.01, ****p < 0.0001, ns = not significant; FPLX5622 = 14.69, p = 0.0012; FIRR = 1.287, p = 0.2715; FInteraction = 29.81, p < 0.0001; n = 6,
two-way ANOVA)
Feng et al. Journal of Neuroinflammation  (2016) 13:215 Page 8 of 13
Fig. 4 (See legend on next page.)
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CSF-1R blockade results in decreased microglia in the
brain
To determine the effects of CSF-1R blockade on micro-
glia, we used flow cytometry analyses to compare num-
bers of microglia between animals treated with PLX5622
and control chows. We observed a significant reduction
of microglia (CD11b+CD45low cells, Fig. 4g) during
PLX5622 treatment. Compared to the control groups,
the PLX5622-treated groups had a 35 % reduction of
microglial population at day −4 (7 days on treatment,
Fig. 4h, p < 0.001) and 50 % reduction at day 3 (14 days
on treatment; Fig. 4i, p < 0.01 ctrl sham vs PLX5622 sham;
p < 0.05 ctrl IRR vs PLX IRR). Consistent with these obser-
vations, myeloid markers expressed in microglia were also
reduced (Additional file 5: Figure S4C and D). However,
microglia numbers fully recovered 4.5 weeks after
PLX5622 withdrawal (data not shown). These results
demonstrate that CSF-1R blockade by PLX5622 causes
temporarily loss of microglia in the brain.
Discussion
Radiotherapy is routinely delivered in fractions to treat
cancers in order to reduce toxicity to normal tissues.
However, most patients who receive WBI, or radiation
to both temporal lobes, will develop cognitive deficits
that can be profoundly disabling. Although conformal
techniques and lowered CNS doses have reduced some
adverse effects, there has been little research in the area
of modifying the cellular response in the CNS following
radiation, with the goal of reducing long-term cognitive
deficits in patients. In this study, we modeled a clinical
treatment paradigm by dividing 10 Gy WBI into three
equal fractions delivered every other day and examined
the cellular and behavioral consequences of that treat-
ment. Our data show that fractionated brain irradiation
results in hippocampal-dependent memory deficits and
loss of dendritic spine density. CSF-1R blockade appears
to rescue memory deficits and dendritic spine density
loss in hippocampal granule neurons in the mouse
model we have studied. Cumulatively, our findings offer
novel insight into the mechanism of radiation-induced
injury and demonstrate that the CSF-1R is a relevant
and rational therapeutic target that could be used clinic-
ally to prevent irradiation-induced sequelae.
We previously reported that a single dose of 10 Gy
WBI selectively disrupts hippocampal-dependent mem-
ory functions by affecting the cellular infrastructure re-
sponsible for plasticity and memory formation [13, 15].
Notably the hippocampus is exquisitely sensitive to WBI
as non-hippocampal functions were intact [15]. Our
current data demonstrate that fractionated radiation
causes persistent cognitive deficits similar to those in-
duced by 10 Gy WBI was delivered as a single dose. The
NOR test examines hippocampal-dependent recognition
memory for objects in rodents, and 1 month after irradi-
ation, the mice had markedly impaired memory function
that persisted up to 3 months. Further assessment of
hippocampal dentate gyrus function with metric distance
test showed significant impairment in animals that re-
ceived fWBI. These cognitive changes are almost cer-
tainly the consequence of the activation of a diverse set
of cellular responses that lead to synaptic alterations.
Interestingly, higher cortical functions involved in episodic-
like and working memory were not significantly affected by
this irradiation paradigm. These data suggest while frac-
tionation may reduce other types of radiation-induced
normal brain injury, the hippocampus remains a select-
ively vulnerable structure.
Dendritic spines are postsynaptic components of exci-
tatory synapses in the CNS. Their structural and density
changes play fundamental role in synaptic functions,
which are crucial for learning and memory [42, 43]. De-
creased density and malformation of dendritic spines have
been observed in neurodegenerative diseases, and loss of
synapses is strongly correlated with cognitive decline
[44, 45]. In the current study, we observed a decrease
of dendritic spine density after fWBI comparable to
what we and others previously reported using a single
dose of 10 Gy WBI [46, 47]. These results suggest that
fractionated irradiation routinely used to treat patients
with primary brain tumors and metastases has substan-
tial deleterious effects, similar to those observed follow-
ing single-dose irradiation.
The exact mechanism of how ionizing radiation leads
to impaired neuronal function, as demonstrated by the
reduction of dendritic spines, is unclear. It is possible
that some of this effect is directly related to DNA and
cellular damage occurring in neurons following irradiation.
(See figure on previous page.)
Fig. 4 CSF-1R blockade reduces blood monocytes and prevents monocyte accumulation in the brain after radiation. a Gating strategy used in flow
cytometry analyses for blood samples. b Comparison of blood monocyte between control and PLX5622-treated animals before irradiation
(**p < 0.01, n = 8, t test). c Analyses of blood monocyte 3 days after the last radiation fraction (*p < 0.05; FPLX5622 = 24.97, p < 0.0001; FIRR = 0.004,
p = 0.95; FInteraction = 0.007, p = 0.93; n = 6, two-way ANOVA). d Gating strategy used in flow cytometry analyses for brain samples. e Comparison of
monocyte population in the brain between control and PLX5622-treated groups before irradiation (n = 8). f Analyses of brain monocytes 3 days after
the last radiation fraction (**p < 0.01, ns = not significant, FPLX5622 = 9.334, p = 0.0045; FIRR = 7.079, p = 0.0121; FInteraction = 9.336, p = 0.0045; n = 9,
two-way ANOVA). g Gating used to distinguish microglia from infiltrating myeloid cells (CD45-low vs CD45-high populations) (h) Comparison
of microglia numbers before irradiation (***p < 0.001, n = 8, t test). i Analyses of microglia numbers 3 days after the last radiation fraction
(*p < 0.05, **p < 0.01, FPLX5622 = 37.54, p = 0.0001; FIRR = 1.602, p = 0.234; FInteraction = 0.3323, p = 0.577; n = 9, two-way ANOVA)
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However, there is also evidence to suggest that other cellu-
lar and molecular pathways activated after brain irradiation
can contribute to neuronal dysfunction. Relevant to our
study, analyses of myeloid cell populations reveal an accu-
mulation of monocytes in the CNS after fWBI. CCR2 is a
chemokine receptor expressed on cells of the myeloid cell
lineage, and we have previously noted that CCR2 deficiency
prevents radiation-induced hippocampal neuronal dysfunc-
tion from a cellular and behavioral perspective [15]. Based
on these results, we postulated that inhibition of monocyte
accumulation could prevent cognitive deficits induced by
cranial irradiation. Because inhibition of CCR2 results in a
more selective inhibition of myeloid cells, we chose to
broadly block monocyte accumulation by treatment with
PLX5622, a small-molecule selective CSF-1R inhibitor,
which was tested in phase I clinical trials (ClinicalTrials.gov
Identifier: NCT01329991 and NCT01282684). CSF-1R is
essential for the survival and differentiation of macrophages
and cells of the monocyte lineage [26, 41]. The association
of increased macrophage infiltration with poor diagnosis in
many types of cancers has led to some interest in targeting
CSF-1R for cancer therapy [48], and studies have shown
that CSF-1R inhibitors have anti-tumor effects [33, 49].
CSF-1R blockade has also showed efficacy in ameliorating
other neuroinflammatory diseases. Gomez-Nicola et al. re-
ported that blockade of CSF-1R with another tyrosine kin-
ase antagonist inhibits microglia proliferation and slows
neuronal damage in prion disease models [50].
Here, we irradiated young adult mice at 2 months of
age (equivalent of 20 years of age in humans [51]) to re-
flect a population in human patients with longer survival
and high risk to develop cognitive deficits after radio-
therapy. We performed cognitive tests when mice were
3–5 months of age (equivalent of 24–30 years of age in
humans [51]) to represent delayed time points when
cognitive deficits are seen in humans. We demonstrate
with flow cytometry analyses that PLX5622 treatment
inhibits Ly6Chigh monocyte accumulation in the brain
after fWBI, possibly due to the reduced numbers of cir-
culating Ly6Chigh monocytes in the peripheral vascula-
ture. We observed a 35–50 % decrease of microglia
number in the brain during PLX5622 treatment, similar
to the data reported by Dagher et al. with an Alzheimer’s
model [32]. The numbers of brain microglia and periph-
eral blood monocyte both recovered after PLX5622
treatment was stopped, and PLX5622 treatment alone
did not affect dendritic spine density or cognitive per-
formance, suggesting that the effect of PLX5622 is tran-
sient and non-toxic. Ten days after fWBI, we observed a
trend toward a decrease in dendritic spine density in
both control and PLX5622-treated groups, but this did
not reach statistical significance. However, at 33 days
after fWBI, there was a statistically significant 20 % re-
duction of spine density in control groups, and CSF-1R
blockade by PLX5622 treatment completely reversed the
spine density loss. Given the limitations of Golgi staining
and the manual scoring method used for dendritic spine
counts [52], it is possible that we underestimated early-
delayed structural and functional changes at 10 days post
fWBI. Dye loading and electrophysiology techniques can
be used in future studies to more accurately assess neur-
onal functions with CSF-1R blockade after fWBI. None-
theless, our results are consistent with previous findings
that suggest radiation-induced cognitive dysfunction is an
ongoing process [3, 4]. We cannot, however, definitively
conclude from our data whether the preserved dendritic
spine density and cognition after fWBI are due to tempor-
arily decreased microglia number or impaired monocyte
accumulation during and immediately after fractionated
brain irradiation. We observed a trend of better per-
formance in the NOR test in PLX5622-treated animals
compared to animals on control diet (Figs. 2b, c,
PLX5622-sham vs control sham). However, given that
PLX5622 specifically acts on the CSF-1R, which is
expressed in myeloid cells, it is unlikely that PLX5622
have direct neurotrophic effects. It is possible that
PLX5622 has secondary anti-inflammatory effects due
to reduced microglia and monocyte numbers in the CNS
during and after radiation. Further studies specifically
targeting either cell population might help answer this
question.
The duration of treatment required to modulate cogni-
tive function is unclear. Several PPAR agonists and RAS
blockers have been shown to be effective in ameliorating
radiation-induced cognitive dysfunctions [53–55]. These
studies all utilized continuous treatments starting from 3
to 7 days before radiation until the end of cognition as-
sessment. In this study, we observe that transiently
inhibiting the CSF-1/CSF-1R signaling reduces micro-
glia number during radiation and blocks monocyte in-
filtration after radiation and is sufficient to ameliorate
fWBI-induced neuronal and cognitive dysfunction. How-
ever, our previous report demonstrated that radiation-
induced inflammation in the brain persists for at least
3 months after a single dose of 10 Gy cranial irradiation
[15]. It is possible that dendritic spine loss in hippo-
campal granule neurons is a secondary effect caused by
radiation-induced inflammation and is an ongoing
process which lasts a substantial period of time. One
limitation of our current study is that we only assessed
dendritic spine density and cognitive performance up
to 1 month after fWBI with PLX5622 treatment. Fur-
ther studies are needed to determine if dendritic spine
loss occurs at longer time points after brain irradiation,
and whether temporary blockade of CSF-1R can per-
manently rescue this effect and ameliorate cognitive
deficits. In addition, given the fact that PLX5622 treat-
ment reduces a substantial portion of microglia, the
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safety, especially long-term effect of CSF-1R blockade,
remains to be tested.
Conclusions
In summary, we demonstrate that transient CSF-1R block-
ade by PLX5622 prevents fWBI-induced memory loss,
which is associated with preservation of dendritic spine
density of hippocampal neurons in the mouse model stud-
ied. Therefore, targeting CSF1R signaling could provide a
possible approach to prevent incidence and severity of
irradiation-induced brain injury.
Additional files
Additional file 1: Figure S1. (A) Experimental paradigm for NOR test.
Mice were allowed to explore the arena for 10 minutes during the
habituation phase (Day 1 and Day 2). On the training phase (Day 3),
mice were allowed to explore the arena for 5 minutes with two identical
objects. On the test phase (Day 4), mice were allowed to explore the arena
for 5 minutes with one familiar object and a novel object. (B) There was no
difference in total time spent exploring both the familiar and the novel
objects between sham and irradiated groups. (C) There was no difference in
distance traveled during the test phase (Day 4) between sham and
irradiated groups. (D) There was no difference in velocity throughout the
DMP test (n = 8). (E) Experimental paradigm for matrix distance test. On
each day each animal went through a 5-minute habituation phase followed
by three 5-minute trials. The distance between two identical objects were
kept at 28 cm during trials 1 and 2, and changed during trial 3. On day 1,
objects were placed with a distance of 14 cm; on day 2, objected were
placed with a distance of 21 cm. (F) and (G) No difference was detected in
total time exploring across trials or groups (n = 8). (TIF 436 kb)
Additional file 2: Figure S2. (A) Bioanalysis of PLX5622 in the blood
and brain. Radiation does not cause increased drug accumulation in the
brain (n = 6). (B) There is no difference in travel distance among groups
(n = 11-12). (C) There is no difference in total exploring time among
groups (n = 11-12). (D) Comparison of dendritic spine densities 10 days
after fWBI (21 days on PLX5622 treatment) shows no significant difference
among groups (n = 5–6). (TIF 238 kb)
Additional file 3: Table S1. Dendritic spine quantification of granule
neurons in dentate gyrus.(XLSX 14 kb)
Additional file 4: Figure S3. Temporal analyses of periphery derived
cells in the brain during and after fWBI. (A) Periphery derived monocytes/
macrophages (Cx3cr1+Ccr2+) changes over time. Significant increase was
observed on 3 days after the last radiation fraction (*p < 0.05). (B) Cx3cr1
+Ccr2+Ly6Clow monocytes changes over time. No significant differences
were observed. (C) RFP-only population changes over time. n = 4–5. (TIF
255 kb)
Additional file 5: Figure S4. PLX5622 treatment does not cause changes
in Ly6Clow monocytes or neutrophil but results in reduced expression of
myeloid cell markers in the brain. (A) Flow cytometry analysis of Ly6Clow
monocytes 3 days after last radiation fraction (n = 6). (B) Flow cytometry
analysis of neutrophils 3 days after the last radiation fraction (n = 6). (C)
Analysis of qPCR results of myeloid markers between control and PLX5622
treated groups before fWBI (*p < 0.05, n = 6). (D) qPCR analyses of myeloid
markers 3 days after the last radiation fraction (*p < 0.05 ctrl_sham vs
PLX_sham, #p < 0.05 ctrl_IRR vs PLX_IRR, n = 6). (TIF 444 kb)
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